Lysergic acid diethylamide is under clinical development by MindBio Therapeutics and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lysergic acid diethylamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lysergic acid diethylamide overview

Lysergic acid diethylamide is under development for the treatment of anxiety disorders, major depressive disorder, and unspecified cancer. The therapeutic candidate acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A). It is administered through sublingual route.

MindBio Therapeutics overview

MindBio Therapeutics is a Pharmaceuticals and Healthcare company that offers drug development services. The company is Headquartered in Melbourne, Victoria, Australia.

For a complete picture of Lysergic acid diethylamide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.